42 assets in Thyroid Cancer

Therapeutic assets addressing Thyroid Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Pembrolizumab Thyroid Cancer	Kineta Inc.	P2	BB (64)
[18f]f-resca-rt4 Thyroid Cancer	RenJi Hospital	P2/3	CCC (55)
[18F]F-RESCA-T4 Thyroid Cancer	RenJi Hospital	P2/3	CCC (55)
[68ga]ga-nota-rt4 Thyroid Cancer	RenJi Hospital	P2/3	CCC (55)
[68ga]ga-nota-t4 Thyroid Cancer	RenJi Hospital	P2/3	CCC (55)
Definity Thyroid Cancer	UNC Lineberger Comprehensive Cancer Center	P2	CCC (53)
Nivolumab Thyroid Cancer	Instituto do Cancer do Estado de São Paulo	P2	CCC (53)
Vebreltinib Thyroid Cancer	Apollomics Inc.	P2	CCC (53)
Tinengotinib Thyroid Cancer	TransThera Sciences (Nanjing), Inc.	P1/2	CCC (52)
Trametinib Thyroid Cancer	Xynomic Pharmaceuticals, Inc.	P1/2	CCC (52)
Cetuximab Thyroid Cancer	Institut de Recherches Internationales Servier	P1/2	CCC (50)
Fluorouracilum Thyroid Cancer	Institut de Recherches Internationales Servier	P1/2	CCC (50)
Atezolizumab Thyroid Cancer	TransThera Sciences (Nanjing), Inc.	P1/2	CCC (48)
H-Gamma1 Heavy Chain Homo Sapiens (1-447) [Vh (Homo Sapiens Ighv4-5901 (99.0%) -(Ighd) -Ighj302 (93.3%) T125>I (114), Cdr-Imgt [8.7.11] (26-33.51-57.96-106)) (1-117) -Homo Sapiens Ighg101, G1M17,1 Ch1 K120, Ch3 D12, L14, 9-G1V21 Ch2 Y15.1, T16, E18 (Ch1 K120 (214) (118-215), Hinge 1-15 (216-230), Ch2 M15.1>Y (252), S16>T (254), T18>E (256) (231-340), Ch3 D12 (356), L14 (358) (341-445), Chs (446-447)) (118-447)], (220-214')-Disulfide With L-Kappa Light Chain Homo Sapiens (1'-214') [V-Kappa (Homo Sapiens Igkv3-1101 (96.8%) -Igkj401 (100%), Cdr-Imgt [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo Sapiens Igkc01 (100%) Km3 A45.1, V101 (Ckappa A45.1 (153'), V101 (191')) (108'-214')]; Dimer (226-226'':229-229'')-Bisdisulfide, Produced In A Cell Line Derived From Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa Thyroid Cancer	Kineta Inc.	P1/2	CCC (48)
Carbon Nanoparticle-Loaded Iron Thyroid Cancer	Sichuan Enray Pharmaceutical Sciences Company	P1/2	CC (45)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Thyroid Cancer	Sensei Biotherapeutics, Inc.	P1/2	CC (45)
jk08 Thyroid Cancer	Salubris Biotherapeutics Inc	P1/2	CC (45)
Lenvatinib Thyroid Cancer	Salubris Biotherapeutics Inc	P1/2	CC (45)
mdx2001 Thyroid Cancer	ModeX Therapeutics, An OPKO Health Company	P1/2	CC (45)
Panitumumab Thyroid Cancer	Institut de Recherches Internationales Servier	P1/2	CC (45)
s241656 Thyroid Cancer	Institut de Recherches Internationales Servier	P1/2	CC (45)
Solnerstotug Thyroid Cancer	Sensei Biotherapeutics, Inc.	P1/2	CC (45)
XP-102 Thyroid Cancer	Xynomic Pharmaceuticals, Inc.	P1/2	CC (45)
Cnsi-Fe Thyroid Cancer	Sichuan Enray Pharmaceutical Sciences Company	P1	CC (44)
Cyclophosphamide Thyroid Cancer	Anusha Kalbasi	P1	CC (43)
Loxo-260 Thyroid Cancer	Eli Lilly and Company	P1	CC (43)
Autologous Anti-Cd19 Car-Expressing T Lymphocytes Thyroid Cancer	Anusha Kalbasi	P1	CC (41)
Binimetinib Thyroid Cancer	Pfizer	P1	CC (41)
Brodalumab Thyroid Cancer	Brian Henick, MD	P1	CC (41)
Claturafenib Thyroid Cancer	Pfizer	P1	CC (41)
Fludarabine Thyroid Cancer	Anusha Kalbasi	P1	CC (41)
Fludeoxyglucose Thyroid Cancer	Anusha Kalbasi	P1	CC (41)
il13ralpha2-specific hinge-optimized 4-1bb-co-stimulatory car/truncated cd19-expressing autologous tn/mem cells Thyroid Cancer	Anusha Kalbasi	P1	CC (41)
Midazolam Thyroid Cancer	Pfizer	P1	CC (41)
Oxaliplatin Thyroid Cancer	Pfizer	P1	CC (41)
pf-07799544 Thyroid Cancer	Pfizer	P1	CC (41)
Slv-154 Thyroid Cancer	Solve Therapeutics	P1	CC (41)
TH19P01-DOCETAXEL Thyroid Cancer	Theratechnologies	P1	CC (41)
inn805 Thyroid Cancer	FindCure Biosciences (ZhongShan) Co., Ltd.	Early P1	C (38)
Dexmedetomidine Thyroid Cancer	Udayana University	N/A	D (30)
Marcaine Thyroid Cancer	Udayana University	N/A	D (30)